Actinium Pharmaceuticals
ATNM
64 hedge funds and large institutions have $45M invested in Actinium Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 11 closing their positions.
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
10% more funds holding
Funds holding: 58 → 64 (+6)
1.65% more ownership
Funds ownership: 16.97% → 18.62% (+1.6%)
2% less capital invested
Capital invested by funds: $46.1M → $45M (-$1.13M)
27% less call options, than puts
Call options by funds: $1.62M | Put options by funds: $2.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.87M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.76M |
| 3 |
SL
Sentinus LLC
Oak Brook,
Illinois
|
+$1.33M |
| 4 |
Jane Street
New York
|
+$1.11M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$2.49M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$2.1M |
| 3 |
Two Sigma Investments
New York
|
-$1.77M |
| 4 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.23M |
| 5 |
Two Sigma Advisers
New York
|
-$1.11M |
ATNM Hedge Fund Activity: Q1 2023 in Review
64 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2023, worth a combined $45M — down 2.5% from $46.1M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ATNM positions and 11 closed out — a net gain of 6 holders — while 22 added to existing stakes and 16 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.87M. The largest seller was D.E. Shaw & Co, cutting an estimated $2.49M.
- 64 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2023, up from 58 in Q4 2022.
- Funds reported $45M of Actinium Pharmaceuticals stock for Q1 2023, down 2.5% quarter-over-quarter.
- 17 funds opened new Actinium Pharmaceuticals positions in Q1 2023 and 11 closed out, a net change of +6 holders.
- The largest Actinium Pharmaceuticals buyer in Q1 2023 was Millennium Management, an estimated $1.87M added.
- The largest Actinium Pharmaceuticals seller in Q1 2023 was D.E. Shaw & Co, an estimated $2.49M sold.
Based on aggregated 13F filings for Q1 2023.